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Controlled cortical impact (CCI) is a mechanical model of traumatic brain injury (TBI) 
that was developed nearly 30 years ago with the goal of creating a testing platform to 
determine the biomechanical properties of brain tissue exposed to direct mechanical 
deformation. Initially used to model TBIs produced by automotive crashes, the CCI 
model rapidly transformed into a standardized technique to study TBI mechanisms 
and evaluate therapies. CCI is most commonly produced using a device that rapidly 
accelerates a rod to impact the surgically exposed cortical dural surface. The tip of the 
rod can be varied in size and geometry to accommodate scalability to difference species. 
Typically, the rod is actuated by a pneumatic piston or electromagnetic actuator. With 
some limits, CCI devices can control the velocity, depth, duration, and site of impact. The 
CCI model produces morphologic and cerebrovascular injury responses that resemble 
certain aspects of human TBI. Commonly observed are graded histologic and axonal 
derangements, disruption of the blood–brain barrier, subdural and intra-parenchymal 
hematoma, edema, inflammation, and alterations in cerebral blood flow. The CCI model 
also produces neurobehavioral and cognitive impairments similar to those observed 
clinically. In contrast to other TBI models, the CCI device induces a significantly pro-
nounced cortical contusion, but is limited in the extent to which it models the diffuse 
effects of TBI; a related limitation is that not all clinical TBI cases are characterized by 
a contusion. Another perceived limitation is that a non-clinically relevant craniotomy is 
performed. Biomechanically, this is irrelevant at the tissue level. However, craniotomies 
are not atraumatic and the effects of surgery should be controlled by including surgical 
sham control groups. CCI devices have also been successfully used to impact closed 
skulls to study mild and repetitive TBI. Future directions for CCI research surround con-
tinued refinements to the model through technical improvements in the devices (e.g., 
minimizing mechanical sources of variation). Like all TBI models, publications should 
report key injury parameters as outlined in the NIH common data elements (CDEs) for 
pre-clinical TBI.
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iNTRODUCTiON AND PURPOSe
Traumatic brain injury (TBI) is a significant worldwide public 
health problem (1–7). Individuals who survive TBI often require 
extensive care, including immediate and emergent care often 
followed by extensive rehabilitation; taken together, this care is 
associated with high direct and indirect costs (8). Unfortunately, 
to date, efforts to develop therapies effective at improving 
outcomes of clinical TBI have fallen short and not led to novel 
FDA-approved therapies for TBI patients. Continued research 
is needed, including the utilization of experimental (i.e., pre-
clinical) TBI models before attempts to translate interventions to 
the clinical setting can be justified.
One of the most widely used models of experimental TBI is 
controlled cortical impact (CCI). Developed in the 1980s, the 
CCI model has been adapted and refined extensively in the years 
since. The purpose of this manuscript is to provide a primer on 
the past and current applications of CCI and discuss consid-
erations for the future of CCI research. In doing so, this review 
will: (1)  provide an overview of the CCI model, (2) synopsize 
the history of the model’s development, (3) highlight the models 
strengths and weaknesses, (4) discuss experimental design 
considerations for researchers using CCI, and (5) identify future 
directions for CCI research along with ways to improve the 
model. When relevant, details regarding information that should 
be reported for CCI studies based on the National Institute of 
Neurological Diseases and Stroke (NINDS) pre-clinical common 
data elements (CDEs) will be noted.
PAST AND PReSeNT APPLiCATiONS: 
MODeL OveRview, DeveLOPMeNT, 
FeATUReS, SUBTYPeS, AND AReAS OF 
iNQUiRY
Overview of the CCi Model
The CCI model was developed in the late 1980s and rapidly 
became one of the most commonly used models of pre-clinical 
TBI. The early devices were pneumatically driven, and more 
recently electromagnetic devices have become available. In the 
following sections, the development of CCI will be summarized 
along with notable applications to date, the key features of CCI 
will be described, and the different devices (pneumatic; electro-
magnetic) will be discussed.
Model Development and Key Applications
For over a century, efforts to understand human TBI have relied 
on utilization of animal models (9–11) to supplement clinical 
evidence. Early studies were characterized by small sample 
sizes, a lack of well-established (i.e., vetted) devices for injury 
induction, and low levels of control over potential confounders. 
Starting in the 1970s, efforts to refine, standardize, and quantify 
experimental brain injury models became increasingly common 
(12–18). Contemporary CCI models owe their lineage to the 
work of Thomas Anderson (19, 20), who was the first to develop 
a neurotrauma model utilizing a constrained-stroke pneumatic 
cylinder mounted on an adjustable crosshead frame to produce 
injury with a high degree of mechanical reproducibility. The CCI 
model was first developed in the late 1980s and early 1990s by 
Lighthall and colleagues to induce TBI in ferrets (21, 22). By 
1991, the device was adapted so that the model could be applied 
to rats (23). After translation to rats, CCI has since been applied 
to mice (24–26), swine (27–30), and non-human primates (31), 
as described in detail later in this review.
Following the initial development and characterization of the 
model, several new applications of CCI device have emerged, 
including options for studying closed head injury (CHI) (32–34). 
The first three decades of CCI research shows some progression 
in the types of research questions addressed. Early applications 
primarily focused on characterizing the model and exploring 
the biomechanical and physiological changes associated with 
injury. Later efforts expanded the histopathological and cellular 
characterization using brain tissue after CCI to identify putative 
secondary injury processes that could not easily or ethically be 
studied in human TBI survivors. CCI has also been used exten-
sively to test novel therapies in the hope of ultimately translating 
promising drugs to clinical care (35–38).
More recently, the expansion of transgenic animals has led to 
applications of CCI to identify important genes and gene products 
that impact injury severity and recovery profiles (39–42). Notably, 
the trend is not linear and ongoing research is being conducted 
in all of the aforementioned areas, with efforts to increasingly 
promote rigor and replication through the use of CDEs. Today, 
CCI remains a mainstay in pre-clinical TBI research.
Key Features of the Model
Traditionally, CCI is a mechanical model of TBI that follows 
anesthetized craniectomy. The CCI device mechanically trans-
fers energy onto the intact dura mater damaging the cortex, and 
sometimes the subcortical structures in cases of more severe 
injury. Applications of CCI are discussed in more detail elsewhere 
in this review. A key feature of CCI is that the injury parameters 
(e.g., depth, velocity, and dwell time) can all be controlled for to 
produce a broad range of TBI severities and well as closed head 
impact by impacting the intact skull.
Device Types and Suppliers
Two main types of CCI devices are commercially available: 
pneumatic and electromagnetic. The original applications of 
the CCI model used a pneumatic device and pneumatic CCI is 
still commonly used today. The electromagnetic alternative was 
developed later but is gaining popularity due to its lower cost 
and greater portability. Both types of CCI are discussed in detail 
below, including a list of commercial suppliers (Table 1).
Pneumatic
When Lighthall and his colleagues first developed the CCI model, 
the device was powered by pressurized gas (i.e., pneumatically 
driven). Pneumatic CCI remains widely used to study TBI 
pathophysiology and test novel therapies (43–45). A typical 
pneumatic CCI device (Figure  1) includes a cylinder, which 
is rigidly mounted to a crossbar. There typically are multiple 
mounting positions on the crossbar so the impactor can be 
vertical or angled, respective to the skull and underlying brain 
FiGURe 2 | electromagnetic controlled cortical impact device (Leica 
Biosystems, Buffalo Grove, iL, USA).FiGURe 1 | Pneumatic controlled cortical impact device (Pittsburgh 
Precision instruments, Pittsburgh, PA, USA).
TABLe 1 | Summary of CCi types and commercial suppliers.
Company (alphabetical) Location Device Notes/comments
Electromagnetic Hatteras Instruments Cary, NC, USA Pinpoint PCI3000 Precision 
Cortical Impactor
 – Removable tips (seven sizes available)
 – Three system configurations
 – Suitable for large animal models when used with articulated 
support arm (accessory unit)
Leica Biosystems Buffalo Grove,  
IL, USA
Impact One Stereotaxic 
Impactor for CCI
 – Removable tips (comes with 1-, 1.5-, 2-, 3-, and 5-mm tips)
Pneumatic Amscien Instruments Richmond,  
VA, USA
Pneumatic (Cortical) Impact 
Device (Model: AMS 201)
 – Accessory unit to measure rod speed is also available




TBI-0310 Impactor  – Removable tip (3 and 5 mm standard)
 – Custom tips for sale
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tissue. Pneumatic CCI devices have a small-bore reciprocating 
double-acting pneumatic piston with a maximum adjustable 
stroke length of approximately 50  mm. This piston functions 
to propel a tip into the exposed neural tissue or, in the case of 
CHI models, the intact skull (discussed elsewhere in this review). 
Depending on the research goals, tips of varied sizes and shapes 
are available, as described later.
Electromagnetic
More recently, electromagnetic CCI devices have become 
available and they share many features with pneumatic devices 
(Figure  2). As with the pneumatic device, the electromagnetic 
alternative is traditionally used in combination with a com-
mercial stereotaxic frame, facilitating adjustment of the impactor 
angle. Some devices are also compatible with an articulated sup-
port arm that can elevate the injury device to facilitate modeling 
CCI in swine and other large animals. The electromagnetic 
device is potentially more portable than pneumatic devices due 
to its smaller size and ability to function without a pressurized 
gas source. A number of options for tip size and shape are also 
available. Like the pneumatic CCI devices, the electromagnetic 
devices are also considered to create a reproducible model of 
brain trauma. Notably, there is little empirical evidence compar-
ing the pneumatic and electromagnetic models; however, one 
study suggested greater reproducibility with electromagnetic CCI 
compared to pneumatic CCI (46).
Commercial Suppliers
Over the last decade, several CCI devices have become avail-
able from commercial suppliers (Table 1). An advantage is that 
CCI standardization is increased. For each category of CCI, the 
company names, locations, and devices are provided. Additional 
details are also provided, including information about the avail-
able tips and accessory units.
Diverse Applications and Other 
Advantages of the CCi Model
Controlled cortical impact has many strengths and, consequently, 
the model has had many applications. Below is a brief overview 
of some of the key strengths of the model. Among the topics 
included are the use of CCI in many species of test subject, the 
TABLe 2 | Summary of species CCi has been used and examples of injury parameters.
Animal (alphabetical) injury site Depth (mm) Dwell time (ms) velocity (ms) Craniectomy size Tip diameter (mm)
Mouse Parietal cortex 0.5–2 50–250 4–6 4–5 mm 3
Rat Parietal cortex; midline 1–3 50–250 4 6–8 mm 5–6
Pig Frontal lobe 12 50–400 2–4 16–18 mm 15
Primate Frontal lobe 7 150 3.5 11–12 mm 10
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clinical relevance of the model, scalability, and control over 
important injury parameters.
Control
A key strength of CCI is the high degree of control over mechani-
cal factors that may affect study findings, including impact depth, 
velocity, dwell time, and volumetric characteristics associated 
with varying impact tip sizes. Additional detail regarding how 
to make decisions about these injury parameters are provided 
later in this review (see Impactor Characteristics: Size, Shape, 
Depth, Velocity, Dwell Time, Angle, and Composition). Beyond 
the CCI parameters, there are general experimental conditions 
that can be controlled, including housing, husbandry, diet, light/
dark cycles, anesthesia (e.g., type; dose; duration), and other 
factors. While physiological and other confounding factors 
are not as tightly controllable, they can be monitored and data 
recorded, including temperature, respiration rate, and light/dark 
cycle. Provided the laboratory is equipped with the necessary 
and properly maintained and calibrated equipment (e.g., heat-
ing pad; temperature probe; ventilation set up), control over 
these parameters adds little additional burden to the researcher. 
Details surrounding variables controlled in CCI studies should 
be reported in accordance with recommended pre-clinical com-
mon data elements (47).
Appropriate for Use in Multiple Species
Another key strength of the CCI model is its scalability, resulting 
in the use of the CCI model in multiple species of test animals. 
For example, CCI has been used in ferrets (21, 22), rats (23, 
48, 49), mice (25, 50–52), swine (27, 30, 53), and non-human 
primates (31). A summary of species used in CCI research is 
provided below (Table 2) along with an example of how injury 
parameters have been set in published studies, though variability 
across studies exists within a single test species. When scaling 
injury parameters across species, a recommended starting point 
is to normalize the percent of brain volume deformed relative to 
the total brain volume. Beyond scaling the injury parameters, 
additional modifications to the device may be necessary; for 
example, the impactor may need to be mounted to an appro-
priately sized frame or used in combination with an articulated 
support arm in order to position the tip above the head of a 
larger animal.
Clinical Relevance
Overall, CCI is considered a clinically relevant pre-clinical TBI 
model by virtue of reproducing many aspects of clinical TBI. 
Topics covered in this review include the pathophysiological and 
functional consequences produced that are similar to what is seen 
clinically, the ability to model TBI across the lifespan, as well as 
applications for evaluating repeated head injury and testing novel 
therapies.
Pathophysiological Consequences That Mimic TBI 
Pathophysiology
One key component of the clinical relevance of the CCI model 
is its ability to produce many of the histopathological changes 
seen in TBI patients. Gross histological changes known to follow 
CCI include: cortical contusion (23, 54–56), disruption of the 
blood–brain-barrier (57, 58), hippocampal cell loss (59–63), and 
overall brain volume loss (64–66). Furthermore, clinical injury 
is characterized by many secondary injury cascades that have 
also been reported as activated after CCI, as evidenced by histo-
logical markers of several processes, including apoptosis (67–71), 
inflammation (64, 71–74), and oxidative stress (74–79). Notably, 
many of the pathophysiological consequences of TBI have been 
found to persist into the chronic period, defined in a recent 
review as persisting at least 2 weeks following experimental TBI 
(80). For example, CCI is known to result in chronic ventricular 
enlargement and shrinkage of gray and white matter (65, 81), 
apoptosis (69, 82, 83), necrosis (24, 84), axonal injury (85), and 
inflammation (86).
Functional Deficits That Model Symptoms 
Experienced by Survivors
Adding to the clinical relevance of CCI is the functional deficits 
in many domains, including overall neurological function (23, 
87, 88), memory (24, 65, 89), learning (90, 91), motor function 
(92–94), and frontal lobe function (95–97). In rodent models, 
these outcomes can be readily assessed using reliable and valid 
tests, including the Morris water maze (65, 90), Barnes maze (25, 
98), elevated plus maze (63), rotarod (99, 100), beam balance task 
(23, 92), beam walking task (23, 24, 87, 93, 98), and attentional 
set-shifting test (AST) (101), to name a few. While standardized 
assessments of functional outcomes are better established in small 
mammals, there are also options for functional outcome testing in 
large mammals, though there remains a relative lack of normative 
data compared to rodents (28). Similar to the pathophysiological 
consequences of CCI, functional deficits often persist into the 
chronic period (102). For example, chronic deficits have been 
reported in frontal lobe dysfunction (95), overall neurological 
function (87, 103–105), motor function (87, 93, 98, 106–110), 
and cognitive function (50, 87–89, 92, 93, 103, 104, 111–116).
Appropriate for Use in Long-Term Survival Studies 
and in Test Animals of All Ages
The CCI model is commonly used and has been used in over 
1000 PubMed-indexed manuscripts. In addition to the afore-
mentioned assets of the model, CCI has a low mortality rate, 
5Osier and Dixon The Controlled Cortical Impact Model
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relative to the fluid percussion model. The high survivability of 
CCI is beneficial in practical ways: it reduces sample attrition, 
keeps study costs down, and assists in the effort to minimize 
animal suffering. CCI’s low mortality rate also facilitates studying 
the chronic effects of TBI. Notably, there is ongoing discussion 
surrounding how long after the initial injury functional impair-
ments, and the underlying pathology, persist. To date, no study 
has followed the natural history of CCI from the time of the initial 
injury to spontaneous death; rather, all published studies sacrifice 
test animals at a controlled time point. In preparing this paper, the 
longest data collection period after CCI identified in published 
papers was 1-year post-injury (65, 117, 118). Interestingly, several 
pathophysiological changes were reported at 1  year after CCI 
induction, including chronic microglial activation (117), lesion 
volume expansion (65, 117), hippocampal neurodegeneration 
(117), ventricular enlargement (65), myelin loss (117), and com-
pensatory responses in cholinergic neurons (65). Only one CCI 
study reported functional deficits a year after TBI, specifically 
poorer performance on the Morris water maze hidden platform 
task and probe trial (65).
The scalability of the CCI model also make it appropriate for 
use in test animals of any age. For example, CCI is commonly 
used model for studying the effects of injury on the immature 
brain as it can be easily scaled down by using a smaller tip 
and driving the tip less deep into the brain tissue (27–29, 48, 
119–121). Similarly, CCI has been used to test outcomes of 
injury later in life, including using mice prone to senescence 
(122–125). Still, most CCI studies use adult male rodents as 
the subjects. Rationale for most studies using male animals is 
that the majority of TBI patients in every age group are male 
(2), and female hormones may influence TBI outcomes (126). 
However, several CCI studies have had samples comprised 
entirely or partly of female test animals (127–130).
Ability to Test the Effects of Closed Head  
Injury and Repetitive Injury
CHI is an additional research application of the CCI device 
(111). A primary advantage to using a CCI impactor over 
weight drop methods is that a higher velocity of the impact can 
be achieved (23). CCI devices have been used to impact the 
exposed skull (46), intact scalp (33), and “helmeted” head (131). 
Frequently, the procedures are set up to allow for some degree of 
head motion after impact. Beyond studying the effects of single 
CHI, CCI is also used to test the effects of repetitive impacts (29, 
33, 34, 66). The effects of CHI and repetitive injury are relevant 
to many clinical populations, including athletes, military per-
sonnel, and victims of domestic violence. Pneumatic impactors 
have also been used to create sports-related head rotational 
acceleration in rats by striking a laterally extended arm of 
a helmet (132). Repetitive injuries using the CCI device are 
associated with worse functional outcomes, when compared to 
a single concussion (33). Currently, the translatability of these 
CHI models to clinical settings is gauged by similarities of the 
pathological responses. For example, CCI–CHI models have 
been reported to produce alterations in clinically relevant cog-
nitive, cerebrovascular, and morphological domains; as well as 
symptoms related to memory; emotion; and sleep (33, 81, 133).
Testing Therapies
Despite the wide variety of therapies that have shown benefit 
in pre-clinical trials, including CCI, none have resulted in an 
FDA-approved therapy for TBI in the United States. Thus, there 
remains an impetus to identify promising therapies in pre-clinical 
models and translate them to clinical trials and ultimately clinical 
care (37, 134). In this effort, CCI represents an important and 
commonly used model; evidence from CCI studies in combina-
tion with other models has led to identification of therapies for 
clinical trials, though the success of these trials has been limited. 
For example, edaravone’s effects and therapeutic window were 
tested in a TBI study (38) and later applied to clinical care of 
TBI in Japan. In the United States, both pre-clinical studies and 
clinical trials of amantadine have shown promise in promoting 
neurobehavioral recovery after TBI (35, 36, 135, 136). It is also 
worth noting that several novel therapies (e.g., hypothermia; 
progesterone; cyclosporine) had successful phase II trials but 
were unable to withstand phase III trials (137–139). Some drugs 
that had been used clinically for symptom management were 
tested for their effects on TBI outcomes in studies using CCI and 
other pre-clinical models, including methylphenidate (140–143), 
amantadine (35), and levetiracetam (144–146). Thus, translation 
between pre-clinical and clinical trials of TBI therapeutics is 
bidirectional.
LiMiTATiONS OF THe CCi MODeL 
AND POTeNTiAL ALTeRNATiveS
Though CCI has many notable strengths, as described above, 
there are some limitations associated with the model. Notably, 
many of these limitations are common to many or all pre-clinical 
TBI models. Only a few limitations are unique to CCI. Later 
in the review, considerations for researchers regarding how to 
minimize these concerns via thoughtful experimental design will 
be extolled.
Concerns Common to Many  
Pre-Clinical Models
The CCI model shares many of the same limitations as other 
common pre-clinical TBI models, because some experimental 
conditions differ substantially from the experiences of TBI 
patients. Being anesthetized at the time of injury may confound 
study findings, though these effects are mitigated by the use of 
sham controls who also receive anesthesia and other identical 
treatment excluding the injury itself. Concerns regarding the 
potential neuroprotective or neural suppressive effects of anes-
thesia as well as ways to mitigate these concerns are discussed 
later in this review (see Considerations for Researchers). 
Similarly, many (but not all) pre-clinical TBI models require a 
surgical procedure prior to the injury itself. In CCI, this is a fairly 
large craniectomy, whereas, in fluid percussion injury (FPI), a 
smaller craniectomy and placement of the leur-loc device occur. 
As with anesthesia, use of sham controls mitigates these con-
cerns. Experimental design choices surrounding craniectomy 
are discussed in additional detail below. A final issue with all 
pre-clinical models is that each produces one or more aspect of 
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clinical TBI consequences (102), but none perfectly mimic the 
entire human condition; researchers must carefully consider the 
outcomes of interest in their study and which TBI model(s) best 
produce deficits in the chosen domains.
It is also worth noting that some of the key assets of pre-
clinical models have associated limitations as well. For example, 
experimental TBI studies are often conducted with unprecedented 
control over sample characteristics that would be impossible 
in clinical trials. This control reduces the possible confounding 
effects of test subject characteristics (e.g., genotype), environ-
mental conditions (e.g., light cycle; diet), and other factors (e.g., 
injury location) on study outcomes. However, since human TBI 
populations are characterized by variability (147), the high-
degree of control in pre-clinical models may limit generalizability 
and slow translation. Commonly, study subjects are comprised 
of only one sex of animals, most often male, and a narrow age 
range. However, NIH has recently required that sex be formally 
considered as a biological variable in new grant applications. 
Diversification of pre-clinical samples or replication of findings in 
different sexes, ages, and species of animals strengthens available 
evidence. Recently, there has been a trend toward diversifying 
TBI samples when possible, although doing so is associated with 
increased costs.
Limitations Specific to CCi
Limitations specific to the CCI model include mechanical vari-
ation, wear on the device, and limited diffuse effects. Discussion 
of how experimental design and regular maintenance can help 
mitigate these concerns is provided in the following section. 
A primary limitation surrounding the CCI device itself, which 
tends to be more complex than other models with respect to its 
mechanical parts. Moreover, the nature of the devices makes 
some vibration and variation inevitable, which can contribute to 
change over time of the relationship between the injury param-
eters and outcome variables. This variability is due in part to the 
breakdown of wearable materials that comprise the pneumatic 
model (e.g., seals) and wear due to friction on electromagnetic 
models; maintenance concerns are discussed later in this review. 
Another limitation of CCI is that, while it models some aspects 
of human TBI well, it cannot capture the full breadth of con-
sequences seen in patients. Moreover, while CCI is an excellent 
model of TBI with contusion, not all human TBIs are character-
ized by contusion. Notably, while some diffuse effects of CCI have 
been reported, they are more limited than with other models 
(e.g., CHI; blast; FPI).
ONGOiNG CCi ReSeARCH: 
CONSiDeRATiONS FOR ReSeARCHeRS 
AND FUTURe DiReCTiONS
Considerations for Researchers
To promote the highest quality CCI research possible, and 
address some of the aforementioned limitations, considerations 
pertaining to experimental design choices for CCI researchers are 
provided below. The discussion covers selection of the test animal, 
decisions surrounding the actual induction of injury (e.g., depth; 
dwell time, and other experimental choices). Following this 
discussion, the role of pilot work will be addressed more broadly.
Selection of Test Animal
Test animal selection should be based on the study goals, keeping 
in mind animal welfare goals to reduce, replace, and refine animal 
models and using the least sentient animal possible to adequately 
address the research question(s). For example, assessing the 
relationship between injury biomechanics and outcomes may 
require use of a primate or porcine brain, which are closer in size 
to human brains than small mammal models. It is also important 
to consider practical aspects surrounding the test animal, such 
as the housing, enrichment, and husbandry requirements, equip-
ment required for behavioral testing, and cost. Finally, ethical 
considerations for working with various test animals should also 
be considered; researchers should review the Guide for Care & 
Use of Laboratory Animals and consult their Institutional Animal 
care and Use Committee (IACUC) for additional guidance.
Decisions Surrounding Injury Parameters
Beyond the decision to use CCI as the TBI induction technique, 
there are many additional choices regarding the injury (e.g., 
depth; tip characteristics; velocity). CCI has been used in a 
large number of studies, each with different experimental goals; 
consequently, the CCI literature is characterized by diversity in 
the specific injury parameters with little standardization. Overall, 
injury parameters typically scale up with the size of the test ani-
mal’s brain and desired injury severity. When making decisions 
surrounding injury parameters, researchers are encouraged to 
carefully consider the goals of their study, published evidence, 
and, whenever possible, pilot data. Considerations for the number 
and location of injury as well as the characteristics of the impactor 
tip (e.g., size, shape, surface material) will be described below.
Impact Location and Number
Commonly, a single injury CCI model is used, though repeated 
injury models have been published (29, 33, 66). In the authors’ 
laboratory, the preferred injury location for rats and mice is on the 
cortical tissue of the right hemisphere. Specifically, the craniec-
tomy is centered between lambda and bregma so that the center 
of the impact tip is AP − 4 mm, R + 4 mm (rats) and AP − 3 mm, 
R + 3 mm (mice). The rationale to use a parasagittal injury site is 
that crossing the sagittal suture (i.e., midline CCI) is associated 
with increased bleeding (23). Researchers can adjust the location 
and number of impact(s) to best meet the needs of their study. 
Some researchers have elected to use bilateral craniectomies in 
an effort to promote lateral movement of tissue while studying 
the effects of two contusions (148, 149). For example, one study 
found that when animals received bilateral mild-injuries, spaced 
a week apart, there was damage to myelin within the corpus cal-
losum at 60 days post-injury that was not present after a single 
contusion (81).
Impactor Characteristics: Size, Shape, Depth, Velocity,  
Dwell Time, Angle, and Composition
Some of the most important considerations for CCI research 
surround the impactor tip, including tip composition, surface 
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material, tip geometry, angle, and dwell time. Depending on the 
device’s commercial supplier, a selection of tips (of varying size 
and composition) may be available off-the-shelf or as a custom 
order. Researchers can also make after-market modifications to 
their tips to meet the goals of the study. Notably, the are 8 pre-
clinical CDEs related to the impactor tip including impactor angle, 
impactor angle measurement, impactor tip shape, impactor tip 
rigidity, impactor depth setting, impactor dwell time, impactor 
velocity, and surface material (47).
Tip size is largely dependent upon the test animal, with the tip 
diameter generally scaling up with the size of the brain (Table 2). 
For instance, 3-mm tips are commonly used for mice and 15-mm 
tips for pigs, with intermediate tip sizes used for rats (5–6 mm), 
ferrets (10 mm), and non-human primates (10 mm). Moreover, 
within an animal model, slightly larger tips may be used to pro-
duce more severe injury, though more commonly injury severity 
is adjusted with increasing impact depth.
The injury depth depends on the zero-point used when set-
ting the desired depth. Notably, there is a lack of standardization 
across labs with some labs zeroing the tip to the skull, other labs 
zeroing the tip to the brain tissue (which occasionally herniates 
slightly after craniectomy), and many groups not specifying in 
publications which zero point was used. The frame of reference 
chosen when zeroing the tip should be noted in publications. 
Importantly, the zero point should be determined while the 
CCI device is statically pressurized (pneumatic) or energized 
(electromechanical) to minimize overshoot from the set level of 
impact depth.
Tip shape is commonly spherical or beveled flat. In the early 
ferret models (21, 22) the tips were spherical. Published CCI 
studies verify that round tips are still used (150, 151); however, 
beveled flat tips have become much more common in recent 
years (24, 51, 123, 152–154). While the emphasis on beveled tips 
occurs in many animal models of CCI, it is especially true when 
the test animals are mice. However, this seems to be largely due 
to convention, as little published empirical evidence surrounding 
the effects of tip shape. One notable study in C57BL6 mice found 
that, compared to round tips, beveled flat tips resulted in a greater 
extent of both neuronal loss and cortical hemorrhaging (155).
As with tip size, depth of injury tends to be scaled up with 
the size of the test animal (Table 2) as well as the desired injury 
severity; however, it is important to note that within a single test 
animal, and injury severity, variation in impact depth occurs. 
Still, scaling impact depth to adjust injury level is common in the 
literature. One study tested four different injury depths (1.5, 1.75, 
2.0, and 2.5 mm) on rat pups (7 and 17 days old, with the older 
animals receiving greater impact depth); in this study, worsening 
MWM performance and histological changes were associated with 
increasing depth of tissue deformation (119). An electromagnetic 
CCI study found that the size of the lesion progressively increased 
with the impact depth (1.5, 2.0, and 2.5 mm), while holding the 
tip size, dwell time, and velocity constant (3.5 mm, 0.1 s, 5.25 m/s, 
respectively); progressive increase in cognitive deficits, but not 
emotional deficits, was also reported with increasing depth (63).
Little empirical evidence surrounding how adjusting the 
velocity affects outcomes. Generally, the consensus is that increas-
ing velocity has some effect on TBI outcomes and the relative 
contribution of contact velocity to injury outcomes is similar in 
both midline and lateral CCI (156). Notably, beyond 3 m/s, depth 
seems to be a greater determinant of injury severity (156). While 
across-study variation in velocity exists in published literature, 
other methodological differences confound interpretation of how 
speed affects outcomes of CCI. Additional evidence that depth is 
more important than velocity in affecting injury severity comes 
from a finite element simulation of CCI (157). In this study, 
increasing the velocity by 100% was associated with increased 
maximum principal strains (MPS) of ~9–26.7% depending on 
brain region (9% in thalamus; 19.5% in deep cortex; 20.2% in 
hippocampus; and 26.7% in superior cortex). Notably, a 50% 
increase in velocity was associated with more modest increases 
in MPS ranging from 1.2 to 13.7% (1.2% in thalamus; 8.5% in 
hippocampus; 12.2% in deep cortex; and 13.7% in superior 
cortex). Conversely, a 35% increase in impact depth (from 2.0 to 
2.7 mm) was associated with increased MPS ranging from 16.6 
to 35.7% (16.6% in deep cortex; 25.8% in hippocampus; 26.1% in 
superior cortex; and 35.7% in thalamus). Thus, larger alterations 
in intracranial responses occur when depth rather than velocity 
is scaled up (157). Still, researchers should use a velocity sensor 
to ensure that the velocity is consistent with the desired setting; 
moreover, researchers should report the velocity of impact as part 
of the TBI pre-clinical CDEs (47).
Other less well-studied considerations regarding injury 
parameters include the orientation of the tip relative to the 
brain tissue or exposed skull, the composition of the tip surface 
material, and the dwell time. With respect to tip surface material, 
most studies use metal tips. However, this need not be the case, 
and some researchers have modified the impactor tip material to 
better meet the study goals (33), as described above. All injury 
parameter decisions should be informed by a thorough review 
of the literature and, whenever possible, pilot data. Also, it is 
important to remember that in order to ensure transparency 
in research and promote replication of findings, reporting of 
injury parameters should be done in accordance with the TBI 
pre-clinical CDE proposed by the NINDS (47).
Injury Severity
It is important to acknowledge that while the injury parameters 
(e.g., depth, tip size, velocity) are manipulated to control the 
injury severity, there is no standardization across labs with respect 
to what constitutes a mild, moderate, or severe injury. Moreover, 
depending on the outcome(s) of interest to the researcher the same 
CCI parameters can result in little-to-no deficit on one outcome 
and severe deficit on another. Thus, it is important for researchers 
to use pilot testing to determine the impact parameters needed to 
produce the extent of deficits desired pathology relevant to the 
clinical level of injury of scientific interest. Commonly, extent 
of injury is made more severe by increasing one or more of the 
following parameters: tip diameter, depth, and velocity. Typically, 
tip diameter and depth are the primary contributors to injury 
severity because early characterization of the model found 
that, beyond 3 m/s, depth seems to be a greater determinant of 
injury severity (156). It should be noted that different clinically 
relevant outcomes may require different CCI impact parameters. 
For example, an impact velocity of 4 m/s, 2.5 mm depth, and a 
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50-ms dwell time using a 5-mm spherical tip has been reported to 
produce a significant motor deficit, but no special memory deficit 
at 2 weeks post-injury (65).
Other Important Choices
Anesthesia
Choices surrounding anesthesia have the potential to impact 
experimental outcomes. Indeed, the NINDS recognizes the 
importance of reporting details about anesthesia as core CDEs 
for all experimental TBI models, including the type, route, and 
duration of anesthesia (47). Careful selection and reporting of 
anesthesia details is important because some agents may confer 
neuroprotection while others may cause neural suppression. 
Furthermore, some post-surgical analgesics promote neural sup-
pression and may impair performance on behavioral testing and 
potentially mask benefits of treatment.
Isoflurane has neuroprotective properties (158) and has been 
associated with less hippocampal damage and fewer behavioral 
deficits when compared to fentanyl-anesthetized animals (159). 
Still, isoflurane remains a popular and widely used anesthetic for 
CCI research as well as other models of experimental brain injury. 
Ketamine is another agent that has been found to have neuro-
protective properties attributed to antagonism of N-methyl-d-
aspartate (NMDA) receptors (160). Similarly, halothane has been 
found to be neuroprotective after CCI (161). Conversely, fentanyl 
contributes to neural suppression (162).
Notably, the confounding effects of anesthesia are mitigated 
when sham animals are used as controls instead of naïve animals. 
There are strategies to reduce the effects of anesthesia. Some 
researchers perform the craniectomy while the animal is anes-
thetized but then discontinue anesthesia and perform impact 
at the time of emergence of the toe-pinch response (119). Less 
commonly, a closed head CCI study was approved that forgoes 
anesthesia altogether. One notable study used a cone-shaped 
bag to comfortably restrain the animals and position the head 
for the impact (33). For researchers who prefer to use anesthesia 
throughout the surgery, the effects of anesthesia can be reduced 
using proper dosing to avoid under- or over-sedation; standard 
assessments, such as the toe-pinch and other tests of reflexes can 
be used to assess the level of sedation in unparalyzed animals.
Craniectomy
There are several aspects of the craniectomy preceding CCI that 
can influence the study findings (80), including the method used 
to produce the craniectomy (163), location of the craniectomy 
(23), number of craniectomies (148, 149), and whether the bone 
flap is replaced (164, 165) or the craniectomy artificially sealed. 
One study found that regardless of whether the craniectomy was 
produced using either a manual trephine or an electric drill there 
were pathophysiological changes, including inflammation and 
evidence of a lesion, when compared to naïve test animals; nota-
bly, in this study the extent of pathophysiological changes were 
greatest when a drill was used (163). Despite this evidence, most 
researchers prefer using a drill to a trephine because it is a con-
venient and efficient method. Obviously, researchers using CCI to 
study CHI do not face these concerns. Those using the invasive 
CCI model can reduce the deleterious effects of craniectomy 
through proficiency in the procedure and careful removal of the 
bone flap. During the procedure, researchers should monitor 
for bleeding, herniation, and dura breech; these complications 
may warrant exclusion of some animals from the final sample. 
Another way to minimize the deleterious effects of craniectomy 
is to limit heat production during drilling; one strategy is to use a 
syringe to apply sterile 0.9% saline solution during the procedure, 
especially if a drill is used. Overall, consistent and clean craniec-
tomy is fundamental in ensuring high-quality CCI research.
Experimental Endpoints
One of the most fundamental choices surrounding all pre-clinical 
models of TBI is the choice of histopathological and functional 
outcome and the details surrounding how variables are measured. 
Choice of outcomes should be based off study goals, and informed 
by a thorough review of the literature. Specifics regarding the 
measurement of each outcome should, whenever possible, be 
based off pilot testing. Beyond choice of a particular behavioral 
test (e.g., MWM), which subtasks to include (e.g., hidden 
platform task, visible platform task, probe trial), and additional 
details (e.g., number of trials; inter-trial interval) must be con-
sidered. A review of the techniques for studying the physiologic 
and behavioral consequences after experimental brain injury, 
including research using the CCI model, has been described in 
detail elsewhere (101, 102).
Comparison of CCI to Other Pre-Clinical 
Neurotrauma Models
There are several experimental TBI research available to research-
ers, most notably CCI, FPI, and blast-induced TBI (bTBI). Each 
model mimics certain histopathological and functional outcomes 
of clinical TBI, but no one model is able to fully represent the 
human condition. Researchers should carefully consider the 
outcomes of interest when choosing a model. CCI is a focal 
model of injury with limited diffuse effects; this is in contrast to 
FPI and bTBI. As described in a recent review (102), long-term 
outcomes of CCI include gross histological changes, ventricular 
enlargement, apoptosis, necrosis, axonal injury, cerebrovascular 
pathology, inflammation, and neurogenesis; CCI also causes 
several long-term deficits in functional status, including overall 
neurological status, motor function, cognitive status, and frontal 
lobe function (102). In contrast to CCI, FPI has not been associ-
ated with long-term changes in gross histology, inflammation, or 
frontal lobe function; however, unlike CCI, FPI causes long-term 
autophagy and stress-related outcomes (102). In contrast to CCI 
and FPI, bTBI is less well-characterized; bTBI has been found 
to cause long-term ventricular enlargement, apoptosis, axonal 
injury, cerebrovascular pathology, inflammation, cognitive dys-
function, and stress-related outcomes (102).
The importance of Regular 
Maintenance of CCi Devices
As is true for all laboratory equipment, high-quality CCI research 
depends on a well-maintained CCI device and related equipment. 
Prior to experiments, researchers should test the CCI device and 
ensure that it is in proper working order and that the piston 
fires freely. It is important to perform preventative maintenance, 
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monitor the device’s performance over time, and make repairs 
accordingly to avoid workflow interruptions and reduced data 
quality. Researchers should consult with the device manufacturer 
surrounding the recommended maintenance plan.
Beyond manufacturer recommendations, considerations for 
the device’s parts, their function, and their structure can inform 
the maintenance routine. For example, pneumatic seals will wear 
over time and may result in leaks and subsequent failure of the 
chamber to fully pressurize, which could affect performance, 
including reducing maximum speed, or even prevent the piston 
from firing altogether. Similarly, in devices where the piston’s 
motion is stopped by a soft surface (e.g., rubber), there will be 
wear over time. Changes in the pressure to velocity calibration 
curve and new mechanical noises are symptoms of a malfunction-
ing device. Depending on the device, these parts will need to be 
replaced periodically; seals may also require periodic lubrication. 
Leaks in the hoses that deliver air to the cylinder can also occur as 
the polymer(s) that comprise this component degrade. It is also 
important to maintain the air compressor (e.g., oil level and tank 
moisture level), and speed-sensor calibration (e.g., periodically; 
after long periods of disuse; when other maintenance is performed 
that results in repositioning of the sensors). Electromagnetic CCI 
device maintenance includes replacing parts that wear due to fric-
tion as the parts move past one another and ensuring electrical 
components remain in proper working order.
Since much of the wear is use-related, laboratories should 
tailor their maintenance schedules of the CCI device based on 
their specific use and needs. Periodic injuring of test animals 
to evaluate for a marker of injury severity (e.g., hematoxylin 
& eosin; cresyl staining), combined with accurate records sur-
rounding how and when the device is used be used to determine 
how many hits the device can deliver before significant varia-
tion occurs so the researcher can ensure replacement parts are 
available. Similarly, high-speed videography is a valuable tool 
that researchers can use to evaluate the approximate extent of 
mechanical variation and monitor for changes over time. Lastly, 
changes in brain edema (wet/dry weights) can be used to monitor 
injury intensity over time.
Guidelines for Publication including 
Common Data elements
The final step in completing high-quality experimental TBI 
research surrounds publication of findings in such a way that 
studies can be replicated. To assist in this effort, the NINDS 
has published a list of CDEs for pre-clinical TBI research stud-
ies (47). Many of the CDEs are common to all pre-clinical TBI 
studies, regardless of the model used, such as characteristics of 
the test animals (e.g., species; strain; commercial supplier; sex; 
age; weight), details regarding animal treatment (e.g., housing; 
husbandry; euthanasia method), and techniques for assessing 
outcomes (e.g., specific tests/measures used; timing of outcome 
assessments). The guidelines also include specific CDEs for 
each injury model. Details regarding CDEs specific to CCI were 
discussed throughout the text of this review, and will be summa-
rized here. Briefly, CCI studies should report: craniectomy size, 
impactor tip details (e.g., shape; size; rigidity; angle); and other 
injury parameters (e.g., dwell time; velocity; depth). Not only do 
these CDEs represent a guide for researchers when publishing 
their data, they may also be useful to researchers in designing CCI 
(and other experimental TBI) studies.
ReMAiNiNG KNOwLeDGe GAPS 
AND FUTURe DiReCTiONS
As contemporary researchers build on the rich history of CCI, 
there remain gaps in the TBI knowledge base and limitations with 
the model. Future directions for CCI research include making 
incremental improvements in the device, enhancing control 
over potential confounders. In the future, findings will be dis-
seminated in a way that promotes replication, by participating in 
the NINDS’s pre-clinical TBI CDEs. Efforts to improve the model 
should include reducing the mechanical variability of the device 
and achieving closer tolerances. Ongoing areas of inquiry include 
application of CCI to more genetically modified test subjects and 
further evaluation of the genomic, epigenomic, proteomic, and 
microbiomic factors underlying injury recovery.
CONCLUSiON
Over 100 years after the first pre-clinical TBI research, experi-
mental models remain a mainstay. Since its development in the 
1980s, the CCI model has become one of the most widely used 
pre-clinical TBI models. Early investigations using this model 
sought to determine the biomechanical properties of brain tis-
sue exposed to direct mechanical deformation, such as those 
associated with automotive crashes. CCI has since been applied 
to evaluate the consequences of open and closed head injury, test 
novel therapies, as well as explore the molecular-genomic factors 
relevant to TBI symptom- and recovery-profiles.
Controlled cortical impact has several notable strengths, 
including a high-degree of control over injury parameters (e.g., 
velocity; depth; duration; and site of impact). The CCI model 
is clinically relevant in that it produces morphologic and cer-
ebrovascular injury responses similar to aspects of human TBI 
and can be used to model injury across the lifespan. Commonly 
observed consequences of CCI include graded histologic and 
axonal derangements, disruption of the blood–brain barrier, sub-
dural and intraparenchymal hematoma, edema, inflammation, 
and alterations in cerebral blood flow. Many functional deficits 
have been observed after CCI as measured using standardized 
behavioral tests. While CCI is characterized by focal loading with 
contusion, diffuse effects have also been reported.
Limitations of CCI include the non-clinically relevant 
craniotomy, use of anesthesia, and potential mechanical varia-
tion. Inclusion of surgical sham control groups and thoughtful 
study design can temper these concerns to some extent. Future 
directions for CCI research include continuing to make technical 
improvements in CCI devices and further expanding the CCI 
knowledge base. In publishing the results of CCI studies (and 
other pre-clinical TBI research), CDEs should be reported in 
accordance with the guidelines set by NINDS for pre-clinical TBI 
research.
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